D-Wave Quantum (QBTS) Gains Commercial Momentum Through Strategic Partnerships and Federal Funding
D-Wave Quantum (QBTS) is distinguishing itself in the quantum computing sector by focusing on quantum annealing to solve complex optimization problems. Unlike competitors focused on general-purpose quantum computing, D-Wave's technology is seeing practical commercial adoption across industries such as manufacturing, telecommunications, and pharmaceuticals. The company has recently secured significant milestones, including a strategic relationship with LG CNS and recognition of its technology in drug discovery research by Shionogi. Furthermore, an agreement with the U.S. Department of Commerce provides D-Wave access to up to $100 million in CHIPS and Science Act funding, potentially accelerating its development roadmap ahead of its third-quarter earnings report on November 10.
Tickers: $IONQ $QBTS $RGTI $SGIOY
Topics: Business Partnerships CHIPS Act Drug Discovery Quantum Computing
Read the full article at Motley Fool
Part of the story D-Wave Quantum (QBTS) Gains Commercial Momentum Through Strategic Partnerships and Federal Funding (2 articles)